INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • 2 hours ago

BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

PRNewsWire • 22 minutes ago

BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or “the Company”) (NASDAQ: BIIB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

GlobeNewsWire • Jun 10, 2026

Congresswoman Who Bought No Stocks In 2025 Is Back With More 2026 Trades: Here's The Shopping List

After not buying or selling any stocks in 2025, a congresswoman who made over $2.4 million in trades in 2024 is buying stocks once again in 2026. Here's a look at the latest transactions.

Benzinga • 18 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

GlobeNewsWire • Jun 9, 2026

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

CVS Health, Pfizer, and Dollar General were among the stocks identified for investors looking for non-tech options.

Barrons • Jun 9, 2026

This Biogen Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga • Jun 8, 2026

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.

Zacks Investment Research • Jun 5, 2026

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

GlobeNewsWire • Jun 4, 2026

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene therapy who had suboptimal clinical status experienced slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersen Salanersen is an investigational antisense oligonucleotide dosed once-yearly with the potential to be a meaningful therapy in the future SMA treatment landscape CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) --   Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular atrophy (SMA).

GlobeNewsWire • Jun 4, 2026